Premium
Human bone chips release of sclerostin and FGF ‐23 into the culture medium: an in vitro pilot study
Author(s) -
Brolese Eliane,
Buser Daniel,
Kuchler Ulrike,
Schaller Benoit,
Gruber Reinhard
Publication year - 2015
Publication title -
clinical oral implants research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.407
H-Index - 161
eISSN - 1600-0501
pISSN - 0905-7161
DOI - 10.1111/clr.12432
Subject(s) - sclerostin , matrix (chemical analysis) , in vitro , chemistry , fibroblast growth factor , demineralized bone matrix , microbiology and biotechnology , bone matrix , medicine , signal transduction , anatomy , biology , biochemistry , materials science , wnt signaling pathway , dbm , cartilage , chromatography , receptor , amplifier , optoelectronics , cmos
Objective Signaling molecules derived from osteocytes have been proposed as a mechanism by which autografts contribute to bone regeneration. However, there have been no studies that determined the role of osteocytes in bone grafts. Material and method Herein, it was examined whether bone chips and demineralized bone matrix release sclerostin and FGF ‐23, both of which are highly expressed by osteocytes. Results Bone grafts from seven donors were placed in culture medium. Immunoassay showed that bone chips released sclerostin (median 1.0 ng/ml) and FGF ‐23 (median 9.8 relative units/ml) within the first day, with declining levels overtime. Demineralized bone matrix also released detectable amounts of sclerostin into culture medium, while FGF ‐23 remained close to the detection limit. In vitro expanded isolated bone cells failed to release detectable amounts of sclerostin and FGF ‐23. Conclusion These results suggest that autografts but also demineralized bone matrix can release signaling molecules that are characteristically produced by osteocytes.